Stockholm and London, 19 September 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products.

Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”),  well recognized for its high-quality genetic toxicology services and strong scientific engagement.

Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.